Colon, Rectum Cancer Cancer
Conditions
Interventions
1. Regimen A: 5-fluorouracil, continuous intravenous infusion
2. Regimen B: 5-fluorouracil, continuous intravenous infusion, plus alpha-interferon five mega units given subcutaneously three times a we
Sponsors
The Royal Marsden NHS Foundation Trust (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histological evidence of metastatic adenocarcinoma of the colon or rectum not amenable to surgery or radiotherapy 2. Patients evaluable for response must have bi-dimensionally measurable disease 3. Patients with no measurable disease 4. No prior treatment with 5-fluorouracil or other cyctotoxic agent or interferon 5. Adequate bone marrow function 6. Life expectancy of greater than 3 months 7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 8. No history of other malignant disease other than non melanotic skin cancer or carcinoma in situ of the cervix 9. No intracerebral metastases or meningeal carcinomatosis 10. No medical contraindications to treatment
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed